Related Experiment Videos

Heparin-surface-modified intraocular lenses in pediatric cataract surgery: prospective randomized study

S Basti1, M K Aasuri, M K Reddy

  • 1Cornea Service, Bausch & Lomb Contact Lens Centre, L.V. Prasad Eye Institute, Hyderabad, India.

Insights

Heparin-surface-modified (HSM) intraocular lenses (IOLs) significantly reduced inflammatory cell deposits in pediatric cataract surgery. These biocompatible IOLs show improved performance compared to unmodified IOLs in children.

Area of Science:

  • Ophthalmology
  • Biomaterials Science
  • Pediatric Surgery

Background:

  • Pediatric cataract surgery requires IOLs with excellent biocompatibility to minimize postoperative inflammation.
  • Inflammatory responses can lead to complications like cell deposits and synechia formation, impacting visual outcomes.
  • Heparin-surface modification (HSM) of IOLs is explored to enhance biocompatibility.

Purpose of the Study:

  • To evaluate the clinical performance of heparin-surface-modified (HSM) poly(methyl methacrylate) (PMMA) intraocular lenses (IOLs) in pediatric eyes.
  • To compare the incidence of inflammatory cell deposits, posterior synechias, and anterior chamber reactions between HSM and unmodified IOLs.

Main Methods:

  • A prospective, randomized, double-masked, controlled trial involving 90 children (aged 2-14 years) with cataract.
  • Patients received either an HSM PMMA IOL (Group 1) or an unmodified PMMA IOL (Group 2).
  • Surgical techniques included extracapsular cataract extraction (ECCE) with IOL implantation, with modifications for younger children.

Main Results:

  • Follow-up at 1 week, 1 month, 3 months, and 6 months included 73-68 patients.
  • Group 1 (HSM IOLs) demonstrated significantly fewer inflammatory cell deposits at 1, 3, and 6 months (P < .001).
  • Posterior synechia formation and anterior chamber reaction were comparable between the two groups.

Conclusions:

  • HSM PMMA IOLs exhibit superior biocompatibility compared to unmodified IOLs in pediatric cataract surgery.
  • The reduced inflammatory cell deposition suggests HSM IOLs are a promising option for pediatric patients.
  • Further research may explore long-term outcomes and benefits of HSM IOLs in pediatric populations.
Abstract

Related Concept Videos